✦ LIBER ✦

PCV54 THE COST-UTILITY OF ALISKIREN IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION. A CANADIAN HEALTH CARE SYSTEM PERSPECTIVE

✍ Scribed by A Lee; SJ Barry; L Leiter; A Nanji; L Annemans; D Tucker; AF Michaliszyn; M Barbeau; G Vincze

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV4: COST ANALYSIS OF AMLODIPINE VERSUS

✍ E Berliner; P Radensky 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PCV72 COST-EFFECTIVENESS ANALYSIS OF ADD

✍ P Kutscherauer; R Kodym; D Bartaskova 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

PMS10 THE COST-EFFECTIVENESS OF ABATACEP

✍ Y Yuan; M Maier-Moldovan; R Maclean; GJ L'Italien 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Cost-effectiveness analysis of TNF-α blo

✍ Simona de Portu; Micol Del Giglio; Gianfranco Altomare; Fabio Arcangeli; Enzo Be 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

Peginterferon alfa-2a versus Peginterfer

✍ Wei-Shi Yeh; Edward P. Armstrong; Grant H. Skrepnek; Daniel C. Malone 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB

PCV101 IS PRASUGREL COST-EFFECTIVE RELAT

✍ A Davies; M Sculpher; C Schmitt; A Barrett; J Clouth; McCollam PL; A Bakhai 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB